Spexis
is headquartered in Allschwil, Basel-Country. Jeffrey D. Wager is the CEO of Spexis. Spexis's latest funding round was a Post-IPO Equity for $2.5M on Aug 2023. Spexis has 1 followers on Owler.Spexis
is headquartered in Allschwil, Basel-Country. Jeffrey D. Wager is the CEO of Spexis. Spexis's latest funding round was a Post-IPO Equity for $2.5M on Aug 2023. Spexis has 1 followers on Owler.
News
Nov 05, 2024
FinanzNachrichten
Spexis: Adhoc: Spexis AG: Spexis expects SIX to delist shares of Spexis on the SIX exchange imminently.
Jul 29, 2024
MarketScreener
Spexis: Spexis granted definitive moratorium status until 25 November 2024, subject to monthly progress report obligations, and which can be potentially extended at the request of the administrators.
Jul 09, 2024
Medthority
Spexis: PARI Pharma GmbH announces termination of ColiFin license to EnBiotix, Inc./Spexis AG
Jun 05, 2024
Medthority
Spexis: Spexis AG appeals against trading suspension
May 31, 2024
MarketScreener
Spexis: Spexis : Annual Report 2023 (Unaudited)
Apr 17, 2024
MarketScreener
Spexis: Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of the lonodelestat license from Santhera
Feb 08, 2024
MarketScreener
Spexis: Spexis announces closing of sale of preclinical antibiotics program to Basilea
Dec 05, 2023
MarketScreener
Spexis: Spexis is Granted Debt-Restructuring Moratorium
Nov 08, 2023
MarketScreener
Spexis: Spexis to file an application for a debt-restructuring moratorium
Nov 01, 2023
MarketScreener
Spexis: Spexis Announces Changes to the Executive Committee